Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Vaccinex Temettü

Temettü kriter kontrolleri 0/6

Vaccinex şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.9%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$10.28
Temettü verim tahmini	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Rock star Growth Puts Vaccinex (NASDAQ:VCNX) In A Position To Use Debt

Aug 17

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: VCNX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: VCNX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Vaccinex Piyasaya Karşı Temettü Getirisi

VCNX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (VCNX)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Biotechs)	1.9%
Analist tahmini (VCNX) (3 yıla kadar)	n/a

Önemli Temettü: VCNX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, VCNX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: VCNX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: VCNX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Vaccinex Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

New major risk - Financial position

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership

Vaccinex, Inc. Reports Positive Data for Signal-Ad Phase 1B/2 Trial of Pepinemab in Alzheimer’S Disease

Insufficient new directors

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease

Vaccinex, Inc. announced that it has received $1.75 million in funding

Vaccinex, Inc. announced delayed annual 10-K filing

Full year 2023 earnings released: US$43.68 loss per share (vs US$98.05 loss in FY 2022)

Vaccinex, Inc. announced that it expects to receive $1.49961 million in funding

Vaccinex, Inc. has filed a Follow-on Equity Offering.

Vaccinex Announces 1-for-14 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of The Nasdaq Capital Market

Vaccinex, Inc. announced that it expects to receive $3.700126 million in funding

New major risk - Market cap size

New major risk - Financial position

Vaccinex, Inc. Reports Clinical Benefit in Interim Analyses from Two Phase 2 Studies of Pepinemab Combination Treatment At Society for Immunotherapy of Cancer's Annual Meeting

Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

Vaccinex Receives Non-Compliance Notice From Nasdaq

Vaccinex's Next Generation ActivMAb®? Technology Published in mAbs

Vaccinex, Inc. to Present Update on PDAC/Pepinemab Study

Vaccinex Reports Groundbreaking Findings At Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer

Vaccinex, Inc. Provides Nasdaq Compliance Update

Vaccinex, Inc. announced that it has received $0.65 million in funding

New major risk - Financial position

New minor risk - Share price stability

Vaccinex Receives Letter from the Listing Qualifications Staff of the Nasdaq Notifying the Company No Longer Complies with the Requirement Under Nasdaq Listing Rule 5550(b)(1)

Vaccinex, Inc. announced that it has received $2.959999 million in funding from FCMI Parent Co.

Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology

Insufficient new directors

Vaccinex, Inc. and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37Th Annual Meeting of Society for Immunotherapy of Cancer

Vaccinex Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market Regarding Minimum Bid Requirement

First half 2022 earnings released: US$0.24 loss per share (vs US$0.47 loss in 1H 2021)

Insufficient new directors

Vaccinex, Inc., Annual General Meeting, May 12, 2022

Vaccinex, Inc. announced that it expects to receive $6.599997 million in funding

Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1B/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (Pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer

Vaccinex, Inc. Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis

Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit

Rock star Growth Puts Vaccinex (NASDAQ:VCNX) In A Position To Use Debt

Price target decreased to US$7.00

Vaccinex, Inc.(NasdaqCM:VCNX) dropped from Russell Microcap Value Index

Vaccinex, Inc. Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer’s Disease

Vaccinex, Inc. Announces Initiation of Phase 2 Clinical Trial with Merck’s anti-PD-1 therapy KEYTRUDA

Surface Oncology, Inc. (NasdaqGM:SURF) acquired worldwide, exclusive, sublicensable license of Vaccinex, Inc. (NasdaqCM:VCNX).

Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology

Vaccinex, Inc. Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform

Vaccinex, Inc. Announces Resignation of Raymond E. Watkins as Senior Vice President and Chief Operating Officer

Vaccinex, Inc. announced that it has received $7.474986 million in funding from FCMI Parent Co., Vaccinex (Rochester), L.L.C and other investors

Vaccinex, Inc. Announces Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab

Vaccinex, Inc. announced that it expects to receive $2 million in funding

Vaccinex, Inc. announced that it has received $8 million in funding

Vaccinex, Inc. announced that it has received $3.999998 million in funding from FCMI Financial Services (Cayman) Ltd.

Vaccinex, Inc. announced that it expects to receive $3.999998 million in funding from FCMI Financial Services (Cayman) Ltd.

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin